# EDGAR Filing Document

**Accession Number:** 0001378872
**File Stem:** 0001752724-23-017350
**Filing Date:** 2023-1
**Character Count:** 100772
**Document Hash:** 1c78b8e5bdd97931e420276868d07919
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001752724-23-017350.hdr.sgml**: 20230130

**ACCESSION NUMBER**: 0001752724-23-017350

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20221130

**FILED AS OF DATE**: 20230130

**DATE AS OF CHANGE**: 20230130

**PERIOD START**: 20230831

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Invesco Exchange-Traded Fund Trust II
- **CENTRAL INDEX KEY:** 0001378872
- **IRS NUMBER:** 000000000
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-21977
- **FILM NUMBER:** 23565279

**BUSINESS ADDRESS:**
- **STREET 1:** 3500 LACEY ROAD
- **STREET 2:** SUITE 700
- **CITY:** DOWNERS GROVE
- **STATE:** IL
- **ZIP:** 60515
- **BUSINESS PHONE:** 800-983-0903

**MAIL ADDRESS:**
- **STREET 1:** 3500 LACEY ROAD
- **STREET 2:** SUITE 700
- **CITY:** DOWNERS GROVE
- **STATE:** IL
- **ZIP:** 60515

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PowerShares Exchange-Traded Fund Trust II
- **DATE OF NAME CHANGE:** 20070919

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PowerShares Global Exchange-Traded Fund Trust
- **DATE OF NAME CHANGE:** 20061023

## Series and Classes Contracts Data

### Invesco PHLX Semiconductor ETF (Series ID: S000072470)

| Class ID   | Class Name                     | Ticker Symbol   |
|:---|:---|:---|
| C000228755 | Invesco PHLX Semiconductor ETF | SOXQ            |

## Nport-Ex

Schedule of Investments<sup>(a)</sup><br>

### Invesco Nasdaq Biotechnology ETF (IBBQ)
November 30, 2022

(Unaudited)

---

| | | |
|:---|:---|:---|
|  | **Shares** | &nbsp;&nbsp;**Value** |
| **Common Stocks & Other Equity Interests-99.98%** | **Common Stocks & Other Equity Interests-99.98%** | **Common Stocks & Other Equity Interests-99.98%** |
| **Biotechnology-81.30%** | **Biotechnology-81.30%** | **Biotechnology-81.30%** |
| 4D Molecular Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;604 | &nbsp;&nbsp;&nbsp;&nbsp;$14599 |
| 89bio, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;861 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6888 |
| Abcam PLC, ADR (United Kingdom)<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;481 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7715 |
| AC Immune S.A. (Switzerland)<sup>(b)</sup><br>| 1554 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3963 |
| Acadia Pharmaceuticals, Inc.<sup>(b)(c)</sup><br>| 3020 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;47052 |
| Achilles Therapeutics PLC, ADR (United Kingdom)<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;723 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1460 |
| Acumen Pharmaceuticals, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;751 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4266 |
| Adaptimmune Therapeutics PLC, ADR<sup>(b)</sup><br>| 2667 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5787 |
| Adicet Bio, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;741 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13471 |
| ADMA Biologics, Inc.<sup>(b)</sup><br>| 3636 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12144 |
| Adverum Biotechnologies, Inc.<sup>(b)</sup><br>| 1848 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1238 |
| Aeglea BioTherapeutics, Inc.<sup>(b)</sup><br>| 1135 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;471 |
| Aerovate Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;452 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8516 |
| Affimed N.V. (Germany)<sup>(b)(c)</sup><br>| 2774 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5936 |
| Agios Pharmaceuticals, Inc.<sup>(b)(c)</sup><br>| 1024 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;30863 |
| Akebia Therapeutics, Inc.<sup>(b)</sup><br>| 3412 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;923 |
| Akero Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;869 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;40409 |
| Alaunos Therapeutics, Inc.<sup>(b)</sup><br>| 4014 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2561 |
| Alector, Inc.<sup>(b)(c)</sup><br>| 1534 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13024 |
| Aligos Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;735 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;735 |
| Alkermes PLC<sup>(b)</sup><br>| 3062 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;75876 |
| Allakos, Inc.<sup>(b)</sup><br>| 1602 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13217 |
| Allogene Therapeutics, Inc.<sup>(b)(c)</sup><br>| 2691 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26533 |
| Allovir, Inc.<sup>(b)</sup><br>| 1729 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12985 |
| Alnylam Pharmaceuticals, Inc.<sup>(b)</sup><br>| 2241 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;494342 |
| Alpine Immune Sciences, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;838 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5263 |
| Altimmune, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;906 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9015 |
| ALX Oncology Holdings, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;752 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8347 |
| Amarin Corp. PLC, ADR (Ireland)<sup>(b)</sup><br>| 7410 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8522 |
| Amgen, Inc.<br>| 6165 | &nbsp;&nbsp;&nbsp;&nbsp;1765656 |
| Amicus Therapeutics, Inc.<sup>(b)(c)</sup><br>| 5227 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;63247 |
| AnaptysBio, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;525 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14506 |
| Anavex Life Sciences Corp.<sup>(b)(c)</sup><br>| 1453 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12815 |
| Annexon, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;887 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4825 |
| Apellis Pharmaceuticals, Inc.<sup>(b)</sup><br>| 2051 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;102406 |
| Applied Molecular Transport, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;718 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;754 |
| Applied Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;895 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1002 |
| Arbutus Biopharma Corp.<sup>(b)</sup><br>| 2787 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6549 |
| Arcturus Therapeutics Holdings, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;495 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9128 |
| Arcutis Biotherapeutics, Inc.<sup>(b)(c)</sup><br>| 1122 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19332 |
| Argenx SE, ADR (Netherlands)<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;568 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;226047 |
| Arrowhead Pharmaceuticals, Inc.<sup>(b)(c)</sup><br>| 1972 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;63498 |
| ARS Pharmaceuticals, Inc.<sup>(b)</sup><br>| 1736 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10798 |
| Ascendis Pharma A/S, ADR (Denmark)<sup>(b)</sup><br>| 1035 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;127367 |
| Atara Biotherapeutics, Inc.<sup>(b)</sup><br>| 1756 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7955 |
| Athenex, Inc.<sup>(b)</sup><br>| 2904 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;610 |
| Aurinia Pharmaceuticals, Inc. (Canada)<sup>(b)(c)</sup><br>| 2657 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13630 |
| Autolus Therapeutics PLC, ADR (United Kingdom)<sup>(b)</sup><br>| 1077 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2843 |
| Avidity Biosciences, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;969 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11279 |
| Avrobio, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;808 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;734 |
| Beam Therapeutics, Inc.<sup>(b)(c)</sup><br>| 1313 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;60647 |
| BeiGene Ltd., ADR (China)<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;902 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;172832 |
| BELLUS Health, Inc. (Canada)<sup>(b)</sup><br>| 2352 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23214 |
| Bicycle Therapeutics PLC, ADR (United Kingdom)<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;473 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13698 |
| BioAtla, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;675 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7432 |
| BioCryst Pharmaceuticals, Inc.<sup>(b)(c)</sup><br>| 3461 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;46239 |
| Biogen, Inc.<sup>(b)</sup><br>| 2710 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;827011 |
| BioMarin Pharmaceutical, Inc.<sup>(b)</sup><br>| 3465 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;349896 |

---

---

| | | |
|:---|:---|:---|
|  | **Shares** | &nbsp;&nbsp;**Value** |
| **Biotechnology-(continued)** | **Biotechnology-(continued)** | **Biotechnology-(continued)** |
| Biomea Fusion, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;541 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$3890 |
| BioNTech SE, ADR (Germany)<br>| &nbsp;&nbsp;1646 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;274915 |
| Black Diamond Therapeutics, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;677 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1428 |
| Bluebird Bio, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;1457 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11350 |
| Blueprint Medicines Corp.<sup>(b)</sup><br>| &nbsp;&nbsp;1117 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;53381 |
| Bolt Biotherapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;702 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1039 |
| Bridgebio Pharma, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;2773 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25983 |
| C4 Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;926 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7936 |
| Cabaletta Bio, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;535 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2397 |
| Candel Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;533 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;933 |
| Caribou Biosciences, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;1128 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10502 |
| Cellectis S.A., ADR (France)<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;335 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;737 |
| Centessa Pharmaceuticals PLC, ADR<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;952 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3808 |
| Century Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;1093 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11477 |
| Chimerix, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;1628 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3533 |
| Chinook Therapeutics, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;1169 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26478 |
| Clovis Oncology, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;2684 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;886 |
| Codiak Biosciences, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;705 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;487 |
| Cogent Biosciences, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;1234 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15524 |
| Coherus Biosciences, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;1461 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10022 |
| Compass Pathways PLC, ADR (United Kingdom)<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;436 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4491 |
| Connect Biopharma Holdings Ltd., ADR (China)<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;785 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;569 |
| Corvus Pharmaceuticals, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;865 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;806 |
| Crinetics Pharmaceuticals, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;1004 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17941 |
| CRISPR Therapeutics AG (Switzerland)<sup>(b)(c)</sup><br>| &nbsp;&nbsp;1458 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;79884 |
| Cullinan Oncology, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;862 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10715 |
| CureVac N.V. (Germany)<sup>(b)</sup><br>| &nbsp;&nbsp;3487 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25281 |
| Curis, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;1704 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1375 |
| Cyteir Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;657 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;946 |
| Cytokinetics, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;1754 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;74545 |
| CytomX Therapeutics, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;1223 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2128 |
| Day One Biopharmaceuticals, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;1377 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;29234 |
| Decibel Therapeutics, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;462 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1418 |
| Deciphera Pharmaceuticals, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;1253 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19935 |
| Denali Therapeutics, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;2534 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;80860 |
| Design Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;1048 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14672 |
| Dyne Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;978 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11443 |
| Eagle Pharmaceuticals, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;243 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8826 |
| Editas Medicine, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;1280 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13568 |
| Eiger BioPharmaceuticals, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;812 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3686 |
| Enanta Pharmaceuticals, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;389 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17034 |
| Erasca, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;2294 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17320 |
| Eterna Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;57 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;186 |
| Evelo Biosciences, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;2006 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4193 |
| Exelixis, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;6007 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;102600 |
| Fate Therapeutics, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;1810 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;37684 |
| FibroGen, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;1757 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25248 |
| Frequency Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;653 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1450 |
| G1 Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;950 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5662 |
| Galapagos N.V., ADR (Belgium)<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;264 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10499 |
| Gamida Cell Ltd. (Israel)<sup>(b)</sup><br>| &nbsp;&nbsp;1342 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2147 |
| Generation Bio Co.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;1091 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5815 |
| Genmab A/S, ADR (Denmark)<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;707 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;32897 |
| Geron Corp.<sup>(b)</sup><br>| &nbsp;&nbsp;7090 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16449 |
| Gilead Sciences, Inc.<br>| 23342 | &nbsp;&nbsp;&nbsp;&nbsp;2050128 |
| Gossamer Bio., Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;1748 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14963 |
| Gracell Biotechnologies, Inc., ADR (China)<sup>(b)</sup><br>| &nbsp;&nbsp;1238 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4024 |
| Graphite Bio, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;1084 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3827 |
| Grifols S.A., ADR (Spain)<sup>(b)</sup><br>| &nbsp;&nbsp;2069 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16862 |
| Gritstone bio, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;1544 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4539 |
| Halozyme Therapeutics, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;2575 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;147445 |

---

See accompanying notes which are an integral part of this schedule.

------

### Invesco Nasdaq Biotechnology ETF (IBBQ)—(continued)<br>
November 30, 2022

(Unaudited)

---

| | | |
|:---|:---|:---|
|  | **Shares** | &nbsp;&nbsp;**Value** |
| **Biotechnology-(continued)** | **Biotechnology-(continued)** | **Biotechnology-(continued)** |
| Harpoon Therapeutics, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;619 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$424 |
| Homology Medicines, Inc.<sup>(b)</sup><br>| 1068 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1645 |
| Horizon Therapeutics PLC<sup>(b)(c)</sup><br>| 4304 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;431648 |
| Humacyte, Inc.<sup>(b)</sup><br>| 1913 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5969 |
| Icosavax, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;738 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2465 |
| Ideaya Biosciences, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;903 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16146 |
| IGM Biosciences, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;542 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11929 |
| I-Mab, ADR (China)<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;990 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3663 |
| Imago Biosciences, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;635 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22663 |
| Immuneering Corp., Class A<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;492 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3193 |
| Immunic, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;732 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;981 |
| ImmunityBio, Inc.<sup>(b)(c)</sup><br>| 7460 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;41105 |
| ImmunoGen, Inc.<sup>(b)</sup><br>| 4127 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21419 |
| Immunovant, Inc.<sup>(b)</sup><br>| 2403 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;31503 |
| Impel Pharmaceuticals, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;437 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1167 |
| Incyte Corp.<sup>(b)</sup><br>| 4155 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;331029 |
| Infinity Pharmaceuticals, Inc.<sup>(b)</sup><br>| 1662 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;912 |
| Inhibrx, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;812 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24344 |
| Inovio Pharmaceuticals, Inc.<sup>(b)(c)</sup><br>| 4679 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9545 |
| Insmed, Inc.<sup>(b)</sup><br>| 2532 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;46817 |
| Instil Bio, Inc.<sup>(b)</sup><br>| 2452 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3261 |
| Intellia Therapeutics, Inc.<sup>(b)</sup><br>| 1418 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;72970 |
| Intercept Pharmaceuticals, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;779 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11615 |
| Ionis Pharmaceuticals, Inc.<sup>(b)(c)</sup><br>| 2648 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;108012 |
| Iovance Biotherapeutics, Inc.<sup>(b)</sup><br>| 2943 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18835 |
| Ironwood Pharmaceuticals, Inc.<sup>(b)(c)</sup><br>| 2854 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;34562 |
| iTeos Therapeutics, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;660 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13299 |
| IVERIC bio, Inc.<sup>(b)(c)</sup><br>| 2206 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;52106 |
| Janux Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;774 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10557 |
| Jounce Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;961 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;846 |
| KalVista Pharmaceuticals, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;454 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2447 |
| Kamada Ltd. (Israel)<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;829 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3896 |
| Karuna Therapeutics, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;634 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;149187 |
| Karyopharm Therapeutics, Inc.<sup>(b)</sup><br>| 1477 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7813 |
| Keros Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;483 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24073 |
| Kezar Life Sciences, Inc.<sup>(b)(c)</sup><br>| 1273 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9942 |
| Kiniksa Pharmaceuticals Ltd., Class A<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;653 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10990 |
| Kinnate Biopharma, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;838 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6637 |
| Kodiak Sciences, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;968 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7144 |
| Kronos Bio, Inc.<sup>(b)(c)</sup><br>| 1055 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2005 |
| Krystal Biotech, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;479 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;37237 |
| Kura Oncology, Inc.<sup>(b)(c)</sup><br>| 1255 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19791 |
| Kymera Therapeutics, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;969 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;28082 |
| Larimar Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;333 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1056 |
| Leap Therapeutics, Inc.<sup>(b)</sup><br>| 1838 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1111 |
| Legend Biotech Corp., ADR<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;995 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;51252 |
| Lexicon Pharmaceuticals, Inc.<sup>(b)</sup><br>| 3408 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7293 |
| Ligand Pharmaceuticals, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;316 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23036 |
| Lyell Immunopharma, Inc.<sup>(b)(c)</sup><br>| 4629 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19488 |
| MacroGenics, Inc.<sup>(b)</sup><br>| 1141 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7337 |
| Madrigal Pharmaceuticals, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;321 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22505 |
| Magenta Therapeutics, Inc.<sup>(b)</sup><br>| 1093 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1257 |
| MannKind Corp.<sup>(b)(c)</sup><br>| 4780 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22370 |
| MeiraGTx Holdings PLC<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;827 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5094 |
| Mereo Biopharma Group PLC, ADR (United Kingdom)<sup>(b)</sup><br>| 2169 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1709 |
| Mersana Therapeutics, Inc.<sup>(b)</sup><br>| 1804 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12015 |
| Merus N.V. (Netherlands)<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;857 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13155 |
| Mirati Therapeutics, Inc.<sup>(b)(c)</sup><br>| 1038 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;94852 |
| Mirum Pharmaceuticals, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;684 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12757 |
| Moderna, Inc.<sup>(b)</sup><br>| 7306 | &nbsp;&nbsp;&nbsp;&nbsp;1285198 |
| Molecular Templates, Inc.<sup>(b)</sup><br>| 1046 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;554 |

---

---

| | | |
|:---|:---|:---|
|  | **Shares** | &nbsp;&nbsp;**Value** |
| **Biotechnology-(continued)** | **Biotechnology-(continued)** | **Biotechnology-(continued)** |
| Monte Rosa Therapeutics, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;868 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$7361 |
| Morphic Holding, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;718 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19759 |
| Mustang Bio, Inc.<sup>(b)</sup><br>| 1949 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;984 |
| Myriad Genetics, Inc.<sup>(b)</sup><br>| 1504 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;30471 |
| Neoleukin Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;794 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;405 |
| Neurocrine Biosciences, Inc.<sup>(b)</sup><br>| 1787 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;227056 |
| NextCure, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;519 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;732 |
| Nkarta, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;914 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7751 |
| Novavax, Inc.<sup>(b)(c)</sup><br>| 1465 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24158 |
| Nurix Therapeutics, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;875 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10841 |
| Nuvalent, Inc., Class A<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;951 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;31269 |
| ObsEva S.A. (Switzerland)<sup>(b)</sup><br>| 1569 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;270 |
| Olema Pharmaceuticals, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;749 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2150 |
| Omega Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;892 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6244 |
| OmniAb, Inc.<sup>(b)</sup><br>| 1541 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5455 |
| OmniAb, Inc.<sup>(b)(d)</sup><br>| &nbsp;&nbsp;&nbsp;125 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 |
| OmniAb, Inc.<sup>(b)(d)</sup><br>| &nbsp;&nbsp;&nbsp;125 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 |
| Oncocyte Corp.<sup>(b)</sup><br>| 2204 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1036 |
| Oncorus, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;483 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;232 |
| ORIC Pharmaceuticals, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;732 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2628 |
| Ovid therapeutics, Inc.<sup>(b)</sup><br>| 1305 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2310 |
| Oyster Point Pharma, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;501 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5601 |
| Passage Bio, Inc.<sup>(b)</sup><br>| 1007 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1229 |
| PMV Pharmaceuticals, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;846 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8443 |
| Poseida Therapeutics, Inc.<sup>(b)(c)</sup><br>| 1590 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7250 |
| Praxis Precision Medicines, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;845 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1867 |
| Precigen, Inc.<sup>(b)</sup><br>| 3858 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7022 |
| Precision BioSciences, Inc.<sup>(b)</sup><br>| 2053 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2813 |
| Prelude Therapeutics, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;891 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5943 |
| Prometheus Biosciences, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;766 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;31490 |
| ProQR Therapeutics N.V. (Netherlands)<sup>(b)</sup><br>| 1385 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1704 |
| Protagonist Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;931 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7364 |
| Prothena Corp. PLC (Ireland)<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;874 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;54634 |
| PTC Therapeutics, Inc.<sup>(b)</sup><br>| 1336 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;55431 |
| Puma Biotechnology, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;845 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3819 |
| Quince Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;671 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;495 |
| Rallybio Corp.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;599 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3450 |
| RAPT Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;557 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9848 |
| Recursion Pharmaceuticals, Inc., Class A<sup>(b)(c)</sup><br>| 3387 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;31838 |
| Regeneron Pharmaceuticals, Inc.<sup>(b)</sup><br>| 2002 | &nbsp;&nbsp;&nbsp;&nbsp;1504903 |
| REGENXBIO, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;807 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19287 |
| Relay Therapeutics, Inc.<sup>(b)(c)</sup><br>| 2246 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;41731 |
| Repare Therapeutics, Inc. (Canada)<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;781 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12519 |
| Replimune Group, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;924 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18914 |
| REVOLUTION Medicines, Inc.<sup>(b)(c)</sup><br>| 1641 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;38711 |
| Rhythm Pharmaceuticals, Inc.<sup>(b)</sup><br>| 1052 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;28162 |
| Rigel Pharmaceuticals, Inc.<sup>(b)</sup><br>| 3206 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2153 |
| Rocket Pharmaceuticals, Inc.<sup>(b)(c)</sup><br>| 1413 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26677 |
| Rubius Therapeutics, Inc.<sup>(b)</sup><br>| 1674 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;372 |
| SAB Biotherapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;803 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;867 |
| Sage Therapeutics, Inc.<sup>(b)(c)</sup><br>| 1111 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;45595 |
| Sana Biotechnology, Inc.<sup>(b)(c)</sup><br>| 3565 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17789 |
| Sangamo Therapeutics, Inc.<sup>(b)(c)</sup><br>| 2942 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10768 |
| Sarepta Therapeutics, Inc.<sup>(b)(c)</sup><br>| 1635 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;200794 |
| Scholar Rock Holding Corp.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;960 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7459 |
| Seagen, Inc.<sup>(b)</sup><br>| 3445 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;418189 |
| Selecta Biosciences, Inc.<sup>(b)(c)</sup><br>| 2833 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3711 |
| Sensei Biotherapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;570 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;809 |
| Sera Prognostics, Inc., Class A<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;547 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;733 |
| Seres Therapeutics, Inc.<sup>(b)(c)</sup><br>| 2306 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14989 |
| Sesen Bio, Inc.<sup>(b)</sup><br>| 3702 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2050 |
| Shattuck Labs, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;790 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1793 |

---

See accompanying notes which are an integral part of this schedule.

------

November 30, 2022

(Unaudited)

---

| | | |
|:---|:---|:---|
|  | **Shares** | &nbsp;&nbsp;**Value** |
| **Biotechnology-(continued)** | **Biotechnology-(continued)** | **Biotechnology-(continued)** |
| Solid Biosciences, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;142 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$951 |
| Spectrum Pharmaceuticals, Inc.<sup>(b)</sup><br>| 3489 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1607 |
| Spero Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;953 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1849 |
| SpringWorks Therapeutics, Inc.<sup>(b)(c)</sup><br>| 1161 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;28073 |
| Stoke Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;729 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5497 |
| Summit Therapeutics, Inc.<sup>(b)</sup><br>| 3726 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2981 |
| Surface Oncology, Inc.<sup>(b)</sup><br>| 1080 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;994 |
| Sutro Biopharma, Inc.<sup>(b)</sup><br>| 1080 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8089 |
| Syndax Pharmaceuticals, Inc.<sup>(b)</sup><br>| 1056 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25302 |
| Syros Pharmaceuticals, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;387 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1533 |
| Talaris Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;776 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1133 |
| Taysha Gene Therapies, Inc.<sup>(b)</sup><br>| 1186 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2621 |
| TCR2 Therapeutics, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;712 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;947 |
| Tenaya Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;769 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2038 |
| Tonix Pharmaceuticals Holding Corp.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;828 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;319 |
| Travere Therapeutics, Inc.<sup>(b)(c)</sup><br>| 1197 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24096 |
| Twist Bioscience Corp.<sup>(b)</sup><br>| 1057 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;28909 |
| Ultragenyx Pharmaceutical, Inc.<sup>(b)</sup><br>| 1303 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;47299 |
| uniQure N.V. (Netherlands)<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;869 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22994 |
| United Therapeutics Corp.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;850 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;237906 |
| UroGen Pharma Ltd.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;427 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3659 |
| Vanda Pharmaceuticals, Inc.<sup>(b)</sup><br>| 1060 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11565 |
| Vaxcyte, Inc.<sup>(b)</sup><br>| 1427 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;65728 |
| Veracyte, Inc.<sup>(b)(c)</sup><br>| 1333 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;36977 |
| Verastem, Inc.<sup>(b)</sup><br>| 3483 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1602 |
| Vertex Pharmaceuticals, Inc.<sup>(b)</sup><br>| 4790 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1515556 |
| Verve Therapeutics, Inc.<sup>(b)</sup><br>| 1123 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26087 |
| Vir Biotechnology, Inc.<sup>(b)</sup><br>| 2477 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;69901 |
| Viracta Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;701 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1626 |
| Vor BioPharma, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;711 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3271 |
| Werewolf Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;545 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;997 |
| Xencor, Inc.<sup>(b)(c)</sup><br>| 1112 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;33049 |
| Xenon Pharmaceuticals, Inc. (Canada)<sup>(b)</sup><br>| 1163 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;42891 |
| Y-mAbs Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;822 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3674 |
| Zai Lab Ltd., ADR (China)<sup>(b)(c)</sup><br>| 1292 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;49820 |
| Zentalis Pharmaceuticals, Inc.<sup>(b)(c)</sup><br>| 1067 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23602 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;16833456 |
| **Health Care Equipment & Supplies-0.74%** | **Health Care Equipment & Supplies-0.74%** | **Health Care Equipment & Supplies-0.74%** |
| Bioventus, Inc., Class A<sup>(b)</sup><br>| 1145 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2233 |
| Novocure Ltd.<sup>(b)(c)</sup><br>| 1957 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;150376 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;152609 |
| **Health Care Providers & Services-0.65%** | **Health Care Providers & Services-0.65%** | **Health Care Providers & Services-0.65%** |
| 23andMe Holding Co., Class A<sup>(b)(c)</sup><br>| 5354 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16330 |
| Castle Biosciences, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;490 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11559 |
| Guardant Health, Inc.<sup>(b)</sup><br>| 1908 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99865 |
| PetIQ, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;541 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6421 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;134175 |
| **Life Sciences Tools & Services-5.13%** | **Life Sciences Tools & Services-5.13%** | **Life Sciences Tools & Services-5.13%** |
| AbCellera Biologics, Inc. (Canada)<sup>(b)(c)</sup><br>| 5318 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;68443 |
| Absci Corp.<sup>(b)</sup><br>| 1725 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4313 |
| Adaptive Biotechnologies Corp.<sup>(b)</sup><br>| 2672 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23460 |
| Alpha Teknova, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;521 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2459 |
| Codex DNA, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;546 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;792 |
| Codexis, Inc.<sup>(b)</sup><br>| 1214 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6641 |
| Compugen Ltd. (Israel)<sup>(b)</sup><br>| 1607 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1928 |
| Harvard Bioscience, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;774 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1981 |
| Illumina, Inc.<sup>(b)</sup><br>| 2938 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;640719 |
| Maravai LifeSciences Holdings, Inc., Class A<sup>(b)</sup><br>| 2454 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;36516 |
| MaxCyte, Inc.<sup>(b)</sup><br>| 1887 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11303 |
| Medpace Holdings, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;578 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;121316 |

---

---

| | | |
|:---|:---|:---|
|  | **Shares** | &nbsp;&nbsp;**Value** |
| **Life Sciences Tools & Services-(continued)** | **Life Sciences Tools & Services-(continued)** | **Life Sciences Tools & Services-(continued)** |
| NanoString Technologies, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;864 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$6039 |
| Nautilus Biotechnology, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;2318 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4196 |
| Pacific Biosciences of California, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;4203 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;45182 |
| Personalis, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;852 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2164 |
| Quantum-Si, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;2221 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5286 |
| Rapid Micro Biosystems, Inc., Class A<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;677 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1388 |
| Seer, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;1092 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7054 |
| Singular Genomics Systems, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;1321 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2695 |
| Syneos Health, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;1912 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;67455 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;1061330 |
| **Pharmaceuticals-12.16%** | **Pharmaceuticals-12.16%** | **Pharmaceuticals-12.16%** |
| Aclaris Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;1251 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19040 |
| Amphastar Pharmaceuticals, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;916 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27013 |
| Aquestive Therapeutics, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;994 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;922 |
| Arvinas, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;992 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;40712 |
| AstraZeneca PLC, ADR (United Kingdom)<br>| 11386 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;773906 |
| ATAI Life Sciences N.V. (Germany)<sup>(b)</sup><br>| &nbsp;&nbsp;3072 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10844 |
| Atea Pharmaceuticals, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;1548 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7260 |
| Athira Pharma, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;706 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2196 |
| Avadel Pharmaceuticals PLC, ADR<sup>(b)</sup><br>| &nbsp;&nbsp;1095 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10041 |
| Axsome Therapeutics, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;751 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;54290 |
| Cara Therapeutics, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;997 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11765 |
| Clearside Biomedical, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;1115 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1349 |
| Collegium Pharmaceutical, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;642 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14041 |
| Cymabay Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;1567 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5296 |
| Edgewise Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;1180 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10561 |
| Esperion Therapeutics, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;1385 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9279 |
| Evolus, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;1065 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7711 |
| EyePoint Pharmaceuticals, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;629 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013 |
| Fulcrum Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;968 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6631 |
| Harmony Biosciences Holdings, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;1103 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;65926 |
| Harrow Health, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;505 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5631 |
| Hutchmed China Ltd., ADR (China)<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;715 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8673 |
| Ikena Oncology, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;674 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1503 |
| Innoviva, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;1304 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17122 |
| Intra-Cellular Therapies, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;1761 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;95481 |
| Jazz Pharmaceuticals PLC<sup>(b)</sup><br>| &nbsp;&nbsp;1171 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;183742 |
| KemPharm, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;638 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3037 |
| Landos Biopharma, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;746 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;160 |
| Marinus Pharmaceuticals, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;878 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4206 |
| Nektar Therapeutics<sup>(b)</sup><br>| &nbsp;&nbsp;3498 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9794 |
| NGM Biopharmaceuticals, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;1504 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8317 |
| NRX Pharmaceuticals, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;1258 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1812 |
| Ocular Therapeutix, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;1429 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4244 |
| Omeros Corp.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;1167 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2497 |
| Optinose, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;1549 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2742 |
| Pacira BioSciences, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;853 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;41157 |
| Paratek Pharmaceuticals, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;1016 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2256 |
| Phathom Pharmaceuticals, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;743 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7415 |
| Phibro Animal Health Corp., Class A<br>| &nbsp;&nbsp;&nbsp;&nbsp;377 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4641 |
| Pliant Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;907 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16671 |
| Provention Bio, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;1530 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13831 |
| Rain Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;347 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2679 |
| Rani Therapeutics Holdings, Inc., Class A<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;453 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3751 |
| Reata Pharmaceuticals, Inc., Class A<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;587 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23233 |
| Redhill Biopharma Ltd., ADR (Israel)<sup>(b)</sup><br>| &nbsp;&nbsp;1186 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;427 |
| Relmada Therapeutics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;557 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2590 |
| Revance Therapeutics, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;1537 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;33368 |
| Royalty Pharma PLC, Class A<br>| &nbsp;&nbsp;8165 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;359015 |
| Sanofi, ADR (France)<br>| &nbsp;&nbsp;5434 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;246432 |
| SIGA Technologies, Inc.<br>| &nbsp;&nbsp;1358 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12466 |
| Supernus Pharmaceuticals, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;1001 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;36757 |

---

See accompanying notes which are an integral part of this schedule.

------

November 30, 2022

(Unaudited)

---

| | | |
|:---|:---|:---|
|  | **Shares** | &nbsp;&nbsp;**Value** |
| **Pharmaceuticals-(continued)** | **Pharmaceuticals-(continued)** | **Pharmaceuticals-(continued)** |
| Terns Pharmaceuticals, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;700 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$5439 |
| Theravance Biopharma, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;1263 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13590 |
| Tricida, Inc.<sup>(b)(c)</sup><br>| &nbsp;&nbsp;1032 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;248 |
| Verrica Pharmaceuticals, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;762 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2476 |
| Viatris, Inc.<br>| 22640 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;249719 |
| WaVe Life Sciences Ltd.<sup>(b)</sup><br>| &nbsp;&nbsp;1611 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6831 |
| Xeris Biopharma Holdings, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;2520 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3780 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2518529 |
| TOTAL INVESTMENTS IN SECURITIES<br>(excluding investments purchased with cash collateral from securities on loan)-99.98%<br>(Cost $25,286,926) | TOTAL INVESTMENTS IN SECURITIES<br>(excluding investments purchased with cash collateral from securities on loan)-99.98%<br>(Cost $25,286,926) | &nbsp;&nbsp;20700099 |

---

---

| | | |
|:---|:---|:---|
|  | **Shares** | &nbsp;&nbsp;**Value** |
| **Investments Purchased with Cash Collateral<br> from Securities on Loan** | **Investments Purchased with Cash Collateral<br> from Securities on Loan** | **Investments Purchased with Cash Collateral<br> from Securities on Loan** |
| **Money Market Funds-14.84%** | **Money Market Funds-14.84%** | **Money Market Funds-14.84%** |
| Invesco Private Government Fund, 3.83%<sup>(e)(f)(g)</sup><br>| &nbsp;&nbsp;&nbsp;860572 | &nbsp;&nbsp;&nbsp;&nbsp;$860572 |
| Invesco Private Prime Fund, 4.15%<sup>(e)(f)(g)</sup><br>| 2211865 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2212308 |
| &nbsp;&nbsp;&nbsp;Total Investments Purchased with Cash Collateral from Securities on Loan<br>(Cost $3,072,523) | &nbsp;&nbsp;&nbsp;Total Investments Purchased with Cash Collateral from Securities on Loan<br>(Cost $3,072,523) | &nbsp;&nbsp;&nbsp;&nbsp;3072880 |
| TOTAL INVESTMENTS IN SECURITIES-114.82%<br>(Cost $28,359,449) | TOTAL INVESTMENTS IN SECURITIES-114.82%<br>(Cost $28,359,449) | &nbsp;&nbsp;23772979 |
| OTHER ASSETS LESS LIABILITIES-(14.82)% | OTHER ASSETS LESS LIABILITIES-(14.82)% | &nbsp;&nbsp;&nbsp;(3067929) |
| NET ASSETS-100.00% | NET ASSETS-100.00% | $20705050 |

---

Investment Abbreviations: <br> ADR -American Depositary Receipt

---

| | |
|:---|:---|
| Notes to Schedule of Investments: | Notes to Schedule of Investments: |
| <sup>(a)</sup> | Industry and/or sector classifications used in this report are generally according to the Global Industry Classification Standard, which was developed by and is the exclusive property and a service mark of MSCI Inc. and Standard & Poor's. |
| <sup>(b)</sup> | Non-income producing security. |
| <sup>(c)</sup> | All or a portion of this security was out on loan at November 30, 2022. |
| <sup>(d)</sup> | Security valued using significant unobservable inputs (Level 3). See Note 1. |
| <sup>(e)</sup> | Affiliated issuer. The issuer and/or the Fund is a wholly-owned subsidiary of Invesco Ltd., or is affiliated by having an investment adviser that is under common control of Invesco Ltd. The table below shows the Fund's transactions in, and earnings from, its investments in affiliates for the three months ended November 30, 2022. |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;&nbsp;**Value<br> August 31, 2022** | &nbsp;&nbsp;&nbsp;**Purchases<br> at Cost** | &nbsp;&nbsp;&nbsp;**Proceeds<br> from Sales** | &nbsp;&nbsp;&nbsp;**Change in<br> Unrealized<br> Appreciation** | &nbsp;&nbsp;&nbsp;**Realized<br> Gain<br> (Loss)** | &nbsp;&nbsp;&nbsp;**Value<br> November 30, 2022** | &nbsp;&nbsp;&nbsp;**Dividend<br> Income** |
| &nbsp;&nbsp;**Investments in Affiliated Money Market Funds:** |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Invesco Government & Agency Portfolio, Institutional Class | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$- | &nbsp;&nbsp;&nbsp;&nbsp;$42485 | &nbsp;&nbsp;&nbsp;&nbsp;$(42485) | &nbsp;&nbsp;&nbsp;&nbsp;$- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$14 |
| &nbsp;&nbsp;**Investments Purchased with Cash Collateral from Securities on Loan:** |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Invesco Private Government Fund | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;749198 | &nbsp;&nbsp;&nbsp;&nbsp;2447208 | &nbsp;&nbsp;&nbsp;&nbsp;(2335834) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;860572 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7,720\* |
| &nbsp;&nbsp;Invesco Private Prime Fund | &nbsp;&nbsp;&nbsp;&nbsp;1937694 | &nbsp;&nbsp;&nbsp;&nbsp;5375243 | &nbsp;&nbsp;&nbsp;&nbsp;(5100624) | &nbsp;&nbsp;&nbsp;&nbsp;272 | &nbsp;&nbsp;&nbsp;&nbsp;(277) | &nbsp;&nbsp;&nbsp;&nbsp;2212308 | &nbsp;&nbsp;&nbsp;&nbsp;21,011\* |
| &nbsp;&nbsp;Total | &nbsp;&nbsp;&nbsp;$2686892 | &nbsp;&nbsp;&nbsp;$7864936 | &nbsp;&nbsp;&nbsp;$(7478943) | &nbsp;&nbsp;&nbsp;$272 | &nbsp;&nbsp;&nbsp;$(277) | &nbsp;&nbsp;&nbsp;$3072880 | &nbsp;&nbsp;&nbsp;$28745 |

---

\* Represents the income earned on the investment of cash collateral. Does not include rebates and fees paid to lending agent or premiums received from borrowers, if any.

<sup>(f)</sup> The rate shown is the 7-day SEC standardized yield as of November 30, 2022. <br> <sup>(g)</sup> The security has been segregated to satisfy the commitment to return the cash collateral received in securities lending transactions upon the borrower's return of the securities loaned.

The valuation policy and a listing of other significant accounting policies are available in the most recent Statement of Additional Information.

See accompanying notes which are an integral part of this schedule.

------

Schedule of Investments<sup>(a)</sup><br>

### Invesco PHLX Semiconductor ETF (SOXQ)
November 30, 2022

(Unaudited)

---

| | | |
|:---|:---|:---|
|  | **Shares** | &nbsp;&nbsp;**Value** |
| **Common Stocks & Other Equity Interests-99.89%** | **Common Stocks & Other Equity Interests-99.89%** | **Common Stocks & Other Equity Interests-99.89%** |
| **Electronic Equipment, Instruments & Components-1.33%** | **Electronic Equipment, Instruments & Components-1.33%** | **Electronic Equipment, Instruments & Components-1.33%** |
| Coherent Corp.<sup>(b)</sup><br>| &nbsp;&nbsp;9656 | &nbsp;&nbsp;&nbsp;$354086 |
| IPG Photonics Corp.<sup>(b)</sup><br>| &nbsp;&nbsp;3707 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;337448 |
| Novanta, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;2623 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;413778 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;1105312 |
| **Life Sciences Tools & Services-0.40%** | **Life Sciences Tools & Services-0.40%** | **Life Sciences Tools & Services-0.40%** |
| Azenta, Inc.<br>| &nbsp;&nbsp;5543 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;333744 |
| **Semiconductors & Semiconductor Equipment-98.16%** | **Semiconductors & Semiconductor Equipment-98.16%** | **Semiconductors & Semiconductor Equipment-98.16%** |
| Advanced Micro Devices, Inc.<sup>(b)</sup><br>| 74468 | &nbsp;&nbsp;&nbsp;&nbsp;5780951 |
| Analog Devices, Inc.<br>| 20845 | &nbsp;&nbsp;&nbsp;&nbsp;3583464 |
| Applied Materials, Inc.<br>| 33595 | &nbsp;&nbsp;&nbsp;&nbsp;3682012 |
| ASML Holding N.V., New York Shares (Netherlands)<br>| &nbsp;&nbsp;6359 | &nbsp;&nbsp;&nbsp;&nbsp;3867035 |
| Broadcom, Inc.<br>| 12666 | &nbsp;&nbsp;&nbsp;&nbsp;6979346 |
| Entegris, Inc.<br>| 11001 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;850267 |
| GLOBALFOUNDRIES, Inc.<sup>(b)(c)</sup><br>| 39893 | &nbsp;&nbsp;&nbsp;&nbsp;2567115 |
| Intel Corp.<br>| 98987 | &nbsp;&nbsp;&nbsp;&nbsp;2976539 |
| KLA Corp.<br>| &nbsp;&nbsp;9182 | &nbsp;&nbsp;&nbsp;&nbsp;3609903 |
| Lam Research Corp.<br>| &nbsp;&nbsp;7228 | &nbsp;&nbsp;&nbsp;&nbsp;3414363 |
| Lattice Semiconductor Corp.<sup>(b)</sup><br>| 10131 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;737841 |
| Marvell Technology, Inc.<br>| 62982 | &nbsp;&nbsp;&nbsp;&nbsp;2929923 |
| Microchip Technology, Inc.<br>| 40810 | &nbsp;&nbsp;&nbsp;&nbsp;3231744 |
| Micron Technology, Inc.<br>| 55907 | &nbsp;&nbsp;&nbsp;&nbsp;3223039 |
| Monolithic Power Systems, Inc.<br>| &nbsp;&nbsp;3446 | &nbsp;&nbsp;&nbsp;&nbsp;1316234 |
| NVIDIA Corp.<br>| 41875 | &nbsp;&nbsp;&nbsp;&nbsp;7086506 |
| NXP Semiconductors N.V. (China)<br>| 19201 | &nbsp;&nbsp;&nbsp;&nbsp;3376304 |
| ON Semiconductor Corp.<sup>(b)</sup><br>| 31998 | &nbsp;&nbsp;&nbsp;&nbsp;2406250 |
| Qorvo, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;7614 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;755689 |
| QUALCOMM, Inc.<br>| 47802 | &nbsp;&nbsp;&nbsp;&nbsp;6046475 |

---

---

| | | |
|:---|:---|:---|
|  | **Shares** | &nbsp;&nbsp;**Value** |
| **Semiconductors & Semiconductor Equipment-(continued)** | **Semiconductors & Semiconductor Equipment-(continued)** | **Semiconductors & Semiconductor Equipment-(continued)** |
| Skyworks Solutions, Inc.<br>| &nbsp;&nbsp;&nbsp;&nbsp;11825 | &nbsp;&nbsp;$1130706 |
| Synaptics, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2935 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;311022 |
| Taiwan Semiconductor Manufacturing Co. Ltd., ADR (Taiwan)<br>| &nbsp;&nbsp;&nbsp;&nbsp;37895 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3144527 |
| Teradyne, Inc.<br>| &nbsp;&nbsp;&nbsp;&nbsp;11578 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1081964 |
| Texas Instruments, Inc.<br>| &nbsp;&nbsp;&nbsp;&nbsp;38274 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6906926 |
| Wolfspeed, Inc.<sup>(b)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9158 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;832645 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;81828790 |
| TOTAL INVESTMENTS IN SECURITIES<br>(excluding investments purchased with cash collateral from securities on loan)-99.89%<br>(Cost $89,527,632) | TOTAL INVESTMENTS IN SECURITIES<br>(excluding investments purchased with cash collateral from securities on loan)-99.89%<br>(Cost $89,527,632) | &nbsp;&nbsp;83267846 |
| **Investments Purchased with Cash Collateral<br> from Securities on Loan** | **Investments Purchased with Cash Collateral<br> from Securities on Loan** | **Investments Purchased with Cash Collateral<br> from Securities on Loan** |
| **Money Market Funds-3.00%** | **Money Market Funds-3.00%** | **Money Market Funds-3.00%** |
| Invesco Private Government Fund, 3.83%<sup>(d)(e)(f)</sup><br>| &nbsp;&nbsp;&nbsp;699270 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;699270 |
| Invesco Private Prime Fund, 4.15%<sup>(d)(e)(f)</sup><br>| 1797270 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1797629 |
| &nbsp;&nbsp;&nbsp;Total Investments Purchased with Cash Collateral from Securities on Loan<br>(Cost $2,496,840) | &nbsp;&nbsp;&nbsp;Total Investments Purchased with Cash Collateral from Securities on Loan<br>(Cost $2,496,840) | &nbsp;&nbsp;&nbsp;&nbsp;2496899 |
| TOTAL INVESTMENTS IN SECURITIES-102.89%<br>(Cost $92,024,472) | TOTAL INVESTMENTS IN SECURITIES-102.89%<br>(Cost $92,024,472) | &nbsp;&nbsp;85764745 |
| OTHER ASSETS LESS LIABILITIES-(2.89)% | OTHER ASSETS LESS LIABILITIES-(2.89)% | &nbsp;&nbsp;&nbsp;(2406490) |
| NET ASSETS-100.00% | NET ASSETS-100.00% | $83358255 |

---

Investment Abbreviations: <br> ADR -American Depositary Receipt

---

| | |
|:---|:---|
| Notes to Schedule of Investments: | Notes to Schedule of Investments: |
| <sup>(a)</sup> | Industry and/or sector classifications used in this report are generally according to the Global Industry Classification Standard, which was developed by and is the exclusive property and a service mark of MSCI Inc. and Standard & Poor's. |
| <sup>(b)</sup> | Non-income producing security. |
| <sup>(c)</sup> | All or a portion of this security was out on loan at November 30, 2022. |
| <sup>(d)</sup> | Affiliated issuer. The issuer and/or the Fund is a wholly-owned subsidiary of Invesco Ltd., or is affiliated by having an investment adviser that is under common control of Invesco Ltd. The table below shows the Fund's transactions in, and earnings from, its investments in affiliates for the three months ended November 30, 2022. |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;&nbsp;**Value<br> August 31, 2022** | &nbsp;&nbsp;&nbsp;**Purchases<br> at Cost** | &nbsp;&nbsp;&nbsp;**Proceeds<br> from Sales** | &nbsp;&nbsp;&nbsp;**Change in<br> Unrealized<br> Appreciation** | &nbsp;&nbsp;&nbsp;**Realized<br> Gain<br> (Loss)** | &nbsp;&nbsp;&nbsp;**Value<br> November 30, 2022** | &nbsp;&nbsp;&nbsp;**Dividend<br> Income** |
| &nbsp;&nbsp;**Investments in Affiliated Money Market Funds:** |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Invesco Government & Agency Portfolio, Institutional Class | &nbsp;&nbsp;&nbsp;$- | &nbsp;&nbsp;&nbsp;&nbsp;$377288 | &nbsp;&nbsp;&nbsp;&nbsp;$(377288) | &nbsp;&nbsp;&nbsp;$- | &nbsp;&nbsp;&nbsp;&nbsp;$- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$- | &nbsp;&nbsp;&nbsp;$117 |
| &nbsp;&nbsp;**Investments Purchased with Cash Collateral from Securities on Loan:** |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Invesco Private Government Fund | &nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4422729 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3723459) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;699270 | &nbsp;&nbsp;&nbsp;&nbsp;2,146\* |
| &nbsp;&nbsp;Invesco Private Prime Fund | &nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;11251661 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(9454028) | &nbsp;&nbsp;&nbsp;&nbsp;59 | &nbsp;&nbsp;&nbsp;&nbsp;(63) | &nbsp;&nbsp;&nbsp;&nbsp;1797629 | &nbsp;&nbsp;&nbsp;&nbsp;5,948\* |
| &nbsp;&nbsp;Total | &nbsp;&nbsp;&nbsp;$- | &nbsp;&nbsp;&nbsp;$16051678 | &nbsp;&nbsp;&nbsp;$(13554775) | &nbsp;&nbsp;&nbsp;$59 | &nbsp;&nbsp;&nbsp;$(63) | &nbsp;&nbsp;&nbsp;$2496899 | &nbsp;&nbsp;&nbsp;$8211 |

---

\* Represents the income earned on the investment of cash collateral. Does not include rebates and fees paid to lending agent or premiums received from borrowers, if any.

See accompanying notes which are an integral part of this schedule.

------

### Invesco PHLX Semiconductor ETF (SOXQ)—(continued)<br>
November 30, 2022

(Unaudited)

<sup>(e)</sup> The rate shown is the 7-day SEC standardized yield as of November 30, 2022. <br> <sup>(f)</sup> The security has been segregated to satisfy the commitment to return the cash collateral received in securities lending transactions upon the borrower's return of the securities loaned.

The valuation policy and a listing of other significant accounting policies are available in the most recent Statement of Additional Information.

See accompanying notes which are an integral part of this schedule.

------

Schedule of Investments<sup>(a)</sup><br>

### Invesco Solar ETF (TAN)
November 30, 2022

(Unaudited)

---

| | | |
|:---|:---|:---|
|  | **Shares** | &nbsp;&nbsp;**Value** |
| **Common Stocks & Other Equity Interests-99.92%** | **Common Stocks & Other Equity Interests-99.92%** | **Common Stocks & Other Equity Interests-99.92%** |
| **Building Products-0.71%** | **Building Products-0.71%** | **Building Products-0.71%** |
| Luoyang Glass Co. Ltd., H Shares (China)<sup>(b)(c)(d)</sup><br>| &nbsp;&nbsp;16604641 | &nbsp;&nbsp;$20343862 |
| **Chemicals-2.87%** | **Chemicals-2.87%** | **Chemicals-2.87%** |
| Hanwha Solutions Corp. (South Korea)<sup>(c)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;2071730 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;82132162 |
| **Construction & Engineering-1.18%** | **Construction & Engineering-1.18%** | **Construction & Engineering-1.18%** |
| ReneSola Ltd., ADR (China)<sup>(c)(d)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;3299822 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15575160 |
| Xinte Energy Co. Ltd., H Shares (China)<br>| &nbsp;&nbsp;&nbsp;&nbsp;7707063 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18296183 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;33871343 |
| **Electrical Equipment-14.36%** | **Electrical Equipment-14.36%** | **Electrical Equipment-14.36%** |
| Array Technologies, Inc.<sup>(c)(d)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;4425567 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;92671374 |
| Heliogen, Inc.<sup>(c)(d)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;6504809 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7415482 |
| Shoals Technologies Group, Inc., Class A<sup>(c)(d)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;3486568 | &nbsp;&nbsp;&nbsp;&nbsp;101005875 |
| Soltec Power Holdings S.A. (Spain)<sup>(c)(d)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;2772521 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13675139 |
| SunPower Corp.<sup>(c)(d)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;2520076 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;61111843 |
| Sunrun, Inc.<sup>(c)(d)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;4132453 | &nbsp;&nbsp;&nbsp;&nbsp;134635319 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;410515032 |
| **Independent Power and Renewable Electricity Producers-19.91%** | **Independent Power and Renewable Electricity Producers-19.91%** | **Independent Power and Renewable Electricity Producers-19.91%** |
| Altus Power, Inc.<sup>(c)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;2255307 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16125445 |
| Atlantica Sustainable Infrastructure PLC (Spain)<br>| &nbsp;&nbsp;&nbsp;&nbsp;2212942 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;61741082 |
| Doral Group Renewable Energy Resources Ltd. (Israel)<sup>(c)(d)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;4229268 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12588918 |
| Encavis AG (Germany)<br>| &nbsp;&nbsp;&nbsp;&nbsp;3781100 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;76821152 |
| Energix-Renewable Energies Ltd. (Israel)<br>| &nbsp;&nbsp;&nbsp;&nbsp;7089144 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26027405 |
| Enlight Renewable Energy Ltd. (Israel)<sup>(c)</sup><br>| &nbsp;&nbsp;21543686 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;48329862 |
| GCL New Energy Holdings Ltd. (China)<sup>(c)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;7943467 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1180504 |
| Grenergy Renovables S.A. (Spain)<sup>(c)(d)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;686320 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23195136 |
| Neoen S.A. (France)<sup>(d)(e)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;1108284 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;44698720 |
| OY Nofar Energy Ltd. (Israel)<sup>(c)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;906519 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26557092 |
| RENOVA, Inc. (Japan)<sup>(c)(d)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;1061078 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21135196 |
| Scatec ASA (South Africa)<sup>(d)(e)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;3073184 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26843991 |
| Solaria Energia y Medio Ambiente S.A. (Spain)<sup>(c)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;2913678 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;52392421 |
| Sunnova Energy International, Inc.<sup>(c)(d)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;2845509 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;64962970 |
| West Holdings Corp. (Japan)<sup>(d)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;1060594 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;33953175 |
| Xinyi Energy Holdings Ltd. (China)<sup>(d)</sup><br>| 106434742 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;32885929 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;569438998 |
| **Mortgage REITs-1.83%** | **Mortgage REITs-1.83%** | **Mortgage REITs-1.83%** |
| Hannon Armstrong Sustainable Infrastructure Capital, Inc.<sup>(d)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;1617119 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;52459341 |

---

---

| | | |
|:---|:---|:---|
|  | **Shares** | &nbsp;&nbsp;**Value** |
| **Semiconductors & Semiconductor Equipment-59.06%** | **Semiconductors & Semiconductor Equipment-59.06%** | **Semiconductors & Semiconductor Equipment-59.06%** |
| Canadian Solar, Inc. (Canada)<sup>(c)(d)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;1809966 | &nbsp;&nbsp;&nbsp;&nbsp;$64887281 |
| Daqo New Energy Corp., ADR (China)<sup>(c)(d)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;1788054 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;101758153 |
| Enphase Energy, Inc.<sup>(c)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;985593 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;315971260 |
| First Solar, Inc.<sup>(c)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;1728104 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;298149783 |
| Flat Glass Group Co. Ltd., H Shares (China)<sup>(d)</sup><br>| &nbsp;&nbsp;17136272 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;44390659 |
| GCL Technology Holdings Ltd. (China)<sup>(c)(d)</sup><br>| 487340221 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;154832025 |
| Gigasolar Materials Corp. (Taiwan)<sup>(c)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;3448000 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12658572 |
| Hyundai Energy Solutions Co. Ltd. (South Korea)<sup>(c)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;344622 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17597285 |
| JinkoSolar Holding Co. Ltd., ADR (China)<sup>(c)(d)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;1327205 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;68059072 |
| Maxeon Solar Technologies Ltd.<sup>(c)(d)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;1151341 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26503870 |
| Meyer Burger Technology AG (Switzerland)<sup>(c)(d)</sup><br>| 113318543 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;61173578 |
| Motech Industries, Inc. (Taiwan)<sup>(b)</sup><br>| &nbsp;&nbsp;24917000 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21051361 |
| SMA Solar Technology AG (Germany)<sup>(c)(d)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;745948 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;48324453 |
| SolarEdge Technologies, Inc.<sup>(c)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;834109 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;249281816 |
| TSEC Corp. (Taiwan)<sup>(b)(c)</sup><br>| &nbsp;&nbsp;24060000 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26088110 |
| United Renewable Energy Co. Ltd. (Taiwan)<sup>(c)</sup><br>| &nbsp;&nbsp;66750458 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;46482939 |
| Xinyi Solar Holdings Ltd. (China)<br>| 112102938 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;131660739 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;1688870956 |
| TOTAL INVESTMENTS IN SECURITIES<br>(excluding investments purchased with cash collateral from securities on loan)-99.92%<br>(Cost $2,965,432,278) | TOTAL INVESTMENTS IN SECURITIES<br>(excluding investments purchased with cash collateral from securities on loan)-99.92%<br>(Cost $2,965,432,278) | &nbsp;&nbsp;2857631694 |
| **Investments Purchased with Cash Collateral<br> from Securities on Loan** | **Investments Purchased with Cash Collateral<br> from Securities on Loan** | **Investments Purchased with Cash Collateral<br> from Securities on Loan** |
| **Money Market Funds-13.43%** | **Money Market Funds-13.43%** | **Money Market Funds-13.43%** |
| Invesco Private Government Fund, 3.83%<sup>(b)(f)(g)</sup><br>| 107550205 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;107550205 |
| Invesco Private Prime Fund, 4.15%<sup>(b)(f)(g)</sup><br>| 276429266 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;276484542 |
| &nbsp;&nbsp;&nbsp;Total Investments Purchased with Cash Collateral from Securities on Loan<br>(Cost $383,992,355) | &nbsp;&nbsp;&nbsp;Total Investments Purchased with Cash Collateral from Securities on Loan<br>(Cost $383,992,355) | &nbsp;&nbsp;&nbsp;&nbsp;384034747 |
| TOTAL INVESTMENTS IN SECURITIES-113.35%<br>(Cost $3,349,424,633) | TOTAL INVESTMENTS IN SECURITIES-113.35%<br>(Cost $3,349,424,633) | &nbsp;&nbsp;3241666441 |
| OTHER ASSETS LESS LIABILITIES-(13.35)% | OTHER ASSETS LESS LIABILITIES-(13.35)% | &nbsp;&nbsp;&nbsp;&nbsp;(381866035) |
| NET ASSETS-100.00% | NET ASSETS-100.00% | $2859800406 |

---

See accompanying notes which are an integral part of this schedule.

------

### Invesco Solar ETF (TAN)—(continued)<br>
November 30, 2022

(Unaudited)

Investment Abbreviations: <br> ADR -American Depositary Receipt

---

| | |
|:---|:---|
| Notes to Schedule of Investments: | Notes to Schedule of Investments: |
| <sup>(a)</sup> | Industry and/or sector classifications used in this report are generally according to the Global Industry Classification Standard, which was developed by and is the exclusive property and a service mark of MSCI Inc. and Standard & Poor's. |
| <sup>(b)</sup> | Affiliated issuer. The issuer is affiliated by having an investment adviser that is under common control of Invesco Ltd. and/or is an "affiliated person" under the Investment Company Act of 1940, as amended (the "1940 Act"), which defines "affiliated person" to include an issuer of which a fund holds 5% or more of the outstanding voting securities. For the Investments in Other Affiliates below, the Fund has not owned enough of the outstanding voting securities of the issuer to have control (as defined in the 1940 Act) of that issuer. The table below shows the Fund's transactions in, and earnings from, its investments in affiliates for the three months ended November 30, 2022. |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;&nbsp;**Value<br> August 31, 2022** | &nbsp;&nbsp;&nbsp;**Purchases<br> at Cost** | &nbsp;&nbsp;&nbsp;**Proceeds<br> from Sales** | &nbsp;&nbsp;&nbsp;**Change in<br> Unrealized<br> Appreciation<br> (Depreciation)** | &nbsp;&nbsp;&nbsp;**Realized<br> Gain<br> (Loss)** | &nbsp;&nbsp;&nbsp;**Value<br> November 30, 2022** | &nbsp;&nbsp;&nbsp;**Dividend<br> Income** |
| &nbsp;&nbsp;**Investments in Affiliated Money Market Funds:** |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Invesco Government & Agency Portfolio, Institutional Class | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$- | &nbsp;&nbsp;&nbsp;$32556823 | &nbsp;&nbsp;&nbsp;$(32556823) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$- | &nbsp;&nbsp;&nbsp;&nbsp;$33916 |
| &nbsp;&nbsp;**Investments Purchased with Cash Collateral from Securities on Loan:** |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Invesco Private Government Fund | &nbsp;&nbsp;&nbsp;&nbsp;190757568 | &nbsp;&nbsp;&nbsp;&nbsp;112662840 | &nbsp;&nbsp;&nbsp;&nbsp;(195870203) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;107550205 | &nbsp;&nbsp;&nbsp;&nbsp;1,026,303\* |
| &nbsp;&nbsp;Invesco Private Prime Fund | &nbsp;&nbsp;&nbsp;&nbsp;493969145 | &nbsp;&nbsp;&nbsp;&nbsp;294273466 | &nbsp;&nbsp;&nbsp;&nbsp;(511760499) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1998 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;432 | &nbsp;&nbsp;&nbsp;&nbsp;276484542 | &nbsp;&nbsp;&nbsp;&nbsp;2,761,413\* |
| &nbsp;&nbsp;**Investments in Other Affiliates:** |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Luoyang Glass Co. Ltd., H Shares | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20436951 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5725717 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2696796) | &nbsp;&nbsp;&nbsp;&nbsp;(2706339) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(415671) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20343862 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- |
| &nbsp;&nbsp;Motech Industries, Inc. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18434760 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8115826 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2964858) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(687679) | &nbsp;&nbsp;&nbsp;&nbsp;(1846688) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21051361 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- |
| &nbsp;&nbsp;TSEC Corp. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;28352920 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6777658 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4119883) | &nbsp;&nbsp;&nbsp;&nbsp;(4036279) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(886306) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26088110 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- |
| &nbsp;&nbsp;Total | &nbsp;&nbsp;&nbsp;$751951344 | &nbsp;&nbsp;&nbsp;$460112330 | &nbsp;&nbsp;&nbsp;$(749969062) | &nbsp;&nbsp;&nbsp;$(7428299) | &nbsp;&nbsp;&nbsp;$(3148233) | &nbsp;&nbsp;&nbsp;$451518080 | &nbsp;&nbsp;&nbsp;$3821632 |

---

\* Represents the income earned on the investment of cash collateral. Does not include rebates and fees paid to lending agent or premiums received from borrowers, if any.

<sup>(c)</sup> Non-income producing security.

<sup>(d)</sup> All or a portion of this security was out on loan at November 30, 2022.

<sup>(e)</sup> Security purchased or received in a transaction exempt from registration under the Securities Act of 1933, as amended (the "1933 Act"). The security may be resold pursuant to an exemption from registration under the 1933 Act, typically to qualified institutional buyers. The aggregate value of these securities at November 30, 2022 was $71,542,711, which represented 2.50% of the Fund's Net Assets.

<sup>(f)</sup> The rate shown is the 7-day SEC standardized yield as of November 30, 2022.

<sup>(g)</sup> The security has been segregated to satisfy the commitment to return the cash collateral received in securities lending transactions upon the borrower's return of the securities loaned.

---

| | |
|:---|:---|
| This Fund has holdings greater than 10% of net assets in the following country: |  |
| China | 20.59% |

---

The valuation policy and a listing of other significant accounting policies are available in the most recent shareholder report.

See accompanying notes which are an integral part of this schedule.

------

### Notes to Quarterly Schedules of Portfolio Holdings
November 30, 2022

(Unaudited)

#### NOTE 1—Additional Valuation Information
Generally Accepted Accounting Principles ("GAAP") defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, under current market conditions. GAAP establishes a hierarchy that prioritizes the inputs to valuation methods, giving the highest priority to readily available unadjusted quoted prices in an active market for identical assets (Level 1) and the lowest priority to significant unobservable inputs (Level 3), generally when market prices are not readily available. Based on the valuation inputs, the securities or other investments are tiered into one of three levels. Changes in valuation methods may result in transfers in or out of an investment's assigned level:

Level 1 — Prices are determined using quoted prices in an active market for identical assets.

Level 2 — Prices are determined using other significant observable inputs. Observable inputs are inputs that other market participants may use in pricing a security. These may include quoted prices for similar securities, interest rates, prepayment speeds, credit risk, yield curves, loss severities, default rates, discount rates, volatilities and others.

Level 3 — Prices are determined using significant unobservable inputs. In situations where quoted prices or observable inputs are unavailable (for example, when there is little or no market activity for an investment at the end of the period), unobservable inputs may be used. Unobservable inputs reflect Invesco Capital Management LLC's assumptions about the factors market participants would use in determining fair value of the securities or instruments and would be based on the best available information.

The following is a summary of the tiered valuation input levels, as of November 30, 2022. The level assigned to the securities valuations may not be an indication of the risk or liquidity associated with investing in those securities. Because of the inherent uncertainties of valuation, the values reflected in the financial statements may materially differ from the value received upon actual sale of those investments.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;&nbsp;**Level 1** | &nbsp;&nbsp;&nbsp;**Level 2** | &nbsp;&nbsp;&nbsp;**Level 3** | &nbsp;&nbsp;&nbsp;**Total** |
| &nbsp;&nbsp;Invesco Nasdaq Biotechnology ETF |  |  |  |  |
| &nbsp;&nbsp;**Investments in Securities** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Common Stocks & Other Equity Interests | &nbsp;&nbsp;&nbsp;&nbsp;$20700099 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$- | &nbsp;&nbsp;&nbsp;$0 | &nbsp;&nbsp;&nbsp;&nbsp;$20700099 |
| &nbsp;&nbsp;&nbsp;Money Market Funds | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3072880 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3072880 |
| &nbsp;&nbsp;&nbsp;**Total Investments** | &nbsp;&nbsp;&nbsp;&nbsp;$20700099 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$3072880 | &nbsp;&nbsp;&nbsp;$0 | &nbsp;&nbsp;&nbsp;&nbsp;$23772979 |
| &nbsp;&nbsp;Invesco PHLX Semiconductor ETF |  |  |  |  |
| &nbsp;&nbsp;**Investments in Securities** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Common Stocks & Other Equity Interests | &nbsp;&nbsp;&nbsp;&nbsp;$83267846 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$- | &nbsp;&nbsp;&nbsp;$- | &nbsp;&nbsp;&nbsp;&nbsp;$83267846 |
| &nbsp;&nbsp;&nbsp;Money Market Funds | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2496899 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2496899 |
| &nbsp;&nbsp;&nbsp;**Total Investments** | &nbsp;&nbsp;&nbsp;&nbsp;$83267846 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$2496899 | &nbsp;&nbsp;&nbsp;$- | &nbsp;&nbsp;&nbsp;&nbsp;$85764745 |
| &nbsp;&nbsp;Invesco Solar ETF |  |  |  |  |
| &nbsp;&nbsp;**Investments in Securities** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Common Stocks & Other Equity Interests | &nbsp;&nbsp;&nbsp;$1733495629 | &nbsp;&nbsp;&nbsp;$1124136065 | &nbsp;&nbsp;&nbsp;$- | &nbsp;&nbsp;&nbsp;$2857631694 |
| &nbsp;&nbsp;&nbsp;Money Market Funds | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;384034747 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;384034747 |
| &nbsp;&nbsp;&nbsp;**Total Investments** | &nbsp;&nbsp;&nbsp;$1733495629 | &nbsp;&nbsp;&nbsp;$1508170812 | &nbsp;&nbsp;&nbsp;$- | &nbsp;&nbsp;&nbsp;$3241666441 |

---

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** Invesco Exchange-Traded Fund Trust II

- **b. Investment Company Act file number:** 811-21977

- **c. CIK number of Registrant:** 0001378872

- **d. LEI of Registrant:** O540V2L4S174Y60FMD36

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 3500 Lacey Road

  - **City:** Downers Grove

  - **State:** IL

  - **Foreign country:** US

  - **Zip / Postal Code:** 60515

  - **Telephone number:** 800-983-0903

**Item A.2. Information about the Series.**

- **a. Name of Series:** Invesco PHLX Semiconductor ETF

- **b. EDGAR series identifier (if any):** S000072470

- **c. LEI of Series:** 5493006ROZOPLBE6WL72

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2023-08-31

- **b. Date as of which information is reported:** 2022-11-30

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $85866444.49

**Total Liabilities:** $2508189.66

**Net Assets:** $83358254.83

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000228755 | -13.73%              | 3.47%                | 18.69%               |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $-2899646.91             | $-5517155.55                               |
| Month 2  | $-104.59                 | $2378085.62                                |
| Month 3  | $178021.64               | $12073926.82                               |

### Schedule of Portfolio Investments

| Name                                        | Title                                            | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Entegris, Inc.                              | Entegris, Inc.                                   | CUSIP: 29362U104<br>LEI: IYX6OWO7BT5DKO3BYG52 | Long             | EC               | CORP              | US        |     11001 | NS      | $850267.29    | 1.02%             |  |  |  | No            |                  1 | On Loan: No      |
| Taiwan Semiconductor Manufacturing Co. Ltd. | Taiwan Semiconductor Manufacturing Co. Ltd., ADR | CUSIP: 874039100<br>LEI: 549300KB6NK5SBD14S87 | Long             | EC               | CORP              | TW        |     37895 | NS      | $3144527.10   | 3.77%             |  |  |  | No            |                  1 | On Loan: No      |
| Microchip Technology Inc.                   | Microchip Technology Inc.                        | CUSIP: 595017104<br>LEI: 5493007PTFULNYZJ1R12 | Long             | EC               | CORP              | US        |     40810 | NS      | $3231743.90   | 3.88%             |  |  |  | No            |                  1 | On Loan: No      |
| NVIDIA Corp.                                | NVIDIA Corp.                                     | CUSIP: 67066G104<br>LEI: 549300S4KLFTLO7GSQ80 | Long             | EC               | CORP              | US        |     41875 | NS      | $7086506.25   | 8.50%             |  |  |  | No            |                  1 | On Loan: No      |
| Lattice Semiconductor Corp.                 | Lattice Semiconductor Corp.                      | CUSIP: 518415104<br>LEI: 549300LRBBPZDQ2II567 | Long             | EC               | CORP              | US        |     10131 | NS      | $737840.73    | 0.89%             |  |  |  | No            |                  1 | On Loan: No      |
| KLA Corp.                                   | KLA Corp.                                        | CUSIP: 482480100<br>LEI: 549300H0BF5JCG96TJ81 | Long             | EC               | CORP              | US        |      9182 | NS      | $3609903.30   | 4.33%             |  |  |  | No            |                  1 | On Loan: No      |
| Intel Corp.                                 | Intel Corp.                                      | CUSIP: 458140100<br>LEI: KNX4USFCNGPY45LOCE31 | Long             | EC               | CORP              | US        |     98987 | NS      | $2976539.09   | 3.57%             |  |  |  | No            |                  1 | On Loan: No      |
| IPG Photonics Corp.                         | IPG Photonics Corp.                              | CUSIP: 44980X109<br>LEI: 5493002KZ51CADQ94G15 | Long             | EC               | CORP              | US        |      3707 | NS      | $337448.21    | 0.40%             |  |  |  | No            |                  1 | On Loan: No      |
| Marvell Technology, Inc.                    | Marvell Technology, Inc.                         | CUSIP: 573874104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     62982 | NS      | $2929922.64   | 3.51%             |  |  |  | No            |                  1 | On Loan: No      |
| Teradyne, Inc.                              | Teradyne, Inc.                                   | CUSIP: 880770102<br>LEI: C3X4YJ278QNZHRJULN75 | Long             | EC               | CORP              | US        |     11578 | NS      | $1081964.10   | 1.30%             |  |  |  | No            |                  1 | On Loan: No      |
| ASML Holding N.V.                           | ASML Holding N.V., New York Shares               | CUSIP: N07059210<br>LEI: 724500Y6DUVHQD6OXN27 | Long             | EC               | CORP              | NL        |      6359 | NS      | $3867035.08   | 4.64%             |  |  |  | No            |                  1 | On Loan: No      |
| Coherent Corp.                              | Coherent Corp.                                   | CUSIP: 19247G107<br>LEI: 549300O5C25A0MMHHU33 | Long             | EC               | CORP              | US        |      9656 | NS      | $354085.52    | 0.42%             |  |  |  | No            |                  1 | On Loan: No      |
| Skyworks Solutions, Inc.                    | Skyworks Solutions, Inc.                         | CUSIP: 83088M102<br>LEI: 549300WZ3ORQ2BVKBD96 | Long             | EC               | CORP              | US        |     11825 | NS      | $1130706.50   | 1.36%             |  |  |  | No            |                  1 | On Loan: No      |
| GLOBALFOUNDRIES Inc.                        | GLOBALFOUNDRIES Inc.                             | CUSIP: G39387108<br>LEI: 549300BA76VK784VMX48 | Long             | EC               | CORP              | KY        |     39893 | NS      | $2567114.55   | 3.08%             |  |  |  | No            |                  1 | On Loan: —       |
| INVESCO PRIVATE GOVERNMENT FUND             | INVESCO PRIVATE GOVERNMENT FUND                  | CUSIP: N/A<br>LEI: N/A                        | Long             | STIV             | PF                | US        |    699270 | NS      | $699270.09    | 0.84%             |  |  |  | No            |                  2 | On Loan: No      |
| Wolfspeed, Inc.                             | Wolfspeed, Inc.                                  | CUSIP: 977852102<br>LEI: 549300OGU88P3AW3TO93 | Long             | EC               | CORP              | US        |      9158 | NS      | $832645.36    | 1.00%             |  |  |  | No            |                  1 | On Loan: No      |
| Broadcom Inc.                               | Broadcom Inc.                                    | CUSIP: 11135F101<br>LEI: 549300WV6GIDOZJTV909 | Long             | EC               | CORP              | US        |     12666 | NS      | $6979345.98   | 8.37%             |  |  |  | No            |                  1 | On Loan: No      |
| Azenta Inc.                                 | Azenta Inc.                                      | CUSIP: 114340102<br>LEI: 35ZN6X1ANPH25YN32Y17 | Long             | EC               | CORP              | US        |      5543 | NS      | $333744.03    | 0.40%             |  |  |  | No            |                  1 | On Loan: No      |
| Advanced Micro Devices, Inc.                | Advanced Micro Devices, Inc.                     | CUSIP: 007903107<br>LEI: R2I72C950HOYXII45366 | Long             | EC               | CORP              | US        |     74468 | NS      | $5780950.84   | 6.94%             |  |  |  | No            |                  1 | On Loan: No      |
| INVESCO PRIVATE PRIME FUND                  | INVESCO PRIVATE PRIME FUND                       | CUSIP: N/A<br>LEI: N/A                        | Long             | STIV             | PF                | US        |   1797270 | NS      | $1797629.33   | 2.16%             |  |  |  | No            |                  2 | On Loan: No      |
| Analog Devices, Inc.                        | Analog Devices, Inc.                             | CUSIP: 032654105<br>LEI: GYVOE5EZ4GDAVTU4CQ61 | Long             | EC               | CORP              | US        |     20845 | NS      | $3583463.95   | 4.30%             |  |  |  | No            |                  1 | On Loan: No      |
| Applied Materials, Inc.                     | Applied Materials, Inc.                          | CUSIP: 038222105<br>LEI: 41BNNE1AFPNAZELZ6K07 | Long             | EC               | CORP              | US        |     33595 | NS      | $3682012.00   | 4.42%             |  |  |  | No            |                  1 | On Loan: No      |
| Synaptics Inc.                              | Synaptics Inc.                                   | CUSIP: 87157D109<br>LEI: 549300AJ3LI4FWNRQX29 | Long             | EC               | CORP              | US        |      2935 | NS      | $311021.95    | 0.37%             |  |  |  | No            |                  1 | On Loan: No      |
| Micron Technology, Inc.                     | Micron Technology, Inc.                          | CUSIP: 595112103<br>LEI: B3DXGBC8GAIYWI2Z0172 | Long             | EC               | CORP              | US        |     55907 | NS      | $3223038.55   | 3.87%             |  |  |  | No            |                  1 | On Loan: No      |
| Novanta Inc.                                | Novanta Inc.                                     | CUSIP: 67000B104<br>LEI: N/A                  | Long             | EC               | CORP              | CA        |      2623 | NS      | $413778.25    | 0.50%             |  |  |  | No            |                  1 | On Loan: No      |
| ON Semiconductor Corp.                      | ON Semiconductor Corp.                           | CUSIP: 682189105<br>LEI: ZV20P4CNJVT8V1ZGJ064 | Long             | EC               | CORP              | US        |     31998 | NS      | $2406249.60   | 2.89%             |  |  |  | No            |                  1 | On Loan: No      |
| NXP Semiconductors N.V.                     | NXP Semiconductors N.V.                          | CUSIP: N6596X109<br>LEI: 724500M9BY5293JDF951 | Long             | EC               | CORP              | NL        |     19201 | NS      | $3376303.84   | 4.05%             |  |  |  | No            |                  1 | On Loan: No      |
| Qorvo, Inc.                                 | Qorvo, Inc.                                      | CUSIP: 74736K101<br>LEI: 254900YAUJV2EUEVBR11 | Long             | EC               | CORP              | US        |      7614 | NS      | $755689.50    | 0.91%             |  |  |  | No            |                  1 | On Loan: No      |
| Qualcomm Inc.                               | Qualcomm Inc.                                    | CUSIP: 747525103<br>LEI: H1J8DDZKZP6H7RWC0H53 | Long             | EC               | CORP              | US        |     47802 | NS      | $6046474.98   | 7.25%             |  |  |  | No            |                  1 | On Loan: No      |
| Lam Research Corp.                          | Lam Research Corp.                               | CUSIP: 512807108<br>LEI: 549300I4GMO6D34U1T02 | Long             | EC               | CORP              | US        |      7228 | NS      | $3414362.64   | 4.10%             |  |  |  | No            |                  1 | On Loan: No      |
| Texas Instruments Inc.                      | Texas Instruments Inc.                           | CUSIP: 882508104<br>LEI: WDJNR2L6D8RWOEB8T652 | Long             | EC               | CORP              | US        |     38274 | NS      | $6906926.04   | 8.29%             |  |  |  | No            |                  1 | On Loan: No      |
| Monolithic Power Systems, Inc.              | Monolithic Power Systems, Inc.                   | CUSIP: 609839105<br>LEI: 529900TB7O85LSZ1XU31 | Long             | EC               | CORP              | US        |      3446 | NS      | $1316234.16   | 1.58%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2022-12-30

**Name of Applicant:** Invesco Exchange-Traded Fund Trust II

**Signature:** Sheri Morris

**Name of Signer:** Sheri Morris

**Title:** Vice President